5-ALA is not just another supplement trend.
It is a biological precursor involved in heme biosynthesis and mitochondrial function.
That is why it has attracted interest in areas such as photodynamic diagnosis, metabolic health, and clinical research.
We have published “A New Understanding of Diabetes.”
This article explains how GDT is exploring diabetes beyond blood sugar control — through diabetes stem cells, 5-ALA, Biozipcode™, and future clinical trials toward fundamental treatment.
https://t.co/IeSxcW0RAY
@Ryu04196650Ryu@Kidney_Int Sleep-related biology and insulin resistance are worth studying, but melatonin findings should be framed as evidence signals, not broad metabolic-health advice.
@JohnHadcock1@DrNikki1984@drterrysimpson Remission definitions matter. HbA1c, fasting glucose, medication status and follow-up duration all need to be specified before comparing outcomes across studies.
@SciTechera Mitochondria are central to metabolic stress, but “support” claims need measurable biology. Functional biomarkers are the bridge from concept to evidence.
@brettboettcher1 Oxidative stress is relevant to insulin resistance research, but supplement claims need the same rigor as drugs: defined endpoints, dosing, safety and replication.
@ObesityAction Metabolic health is broader than weight. The most useful conversations connect symptoms and habits to measurable risk markers, not appearance alone.
@SamaHoole Visceral fat and insulin resistance can be missed when BMI is used alone. Population-specific biomarker validation is essential for fair metabolic risk assessment.
@drwilliamli GLP-1 is a good example of physiology becoming therapeutics. The broader lesson is to study endogenous pathways with careful endpoints, not oversimplified health claims.
@singularityhub Mitochondrial delivery is a fascinating frontier. For metabolic disease, the hard questions are cell targeting, durability, safety and functional biomarkers.
@FrontEndocrinol Predictors of response are often under-discussed. For type 2 diabetes, stratification biomarkers may matter as much as the drug class being compared.
@Being_creat_ive This is an important biomarker-equity issue. HbA1c interpretation can vary by physiology and population context, so validation across groups matters.
@healthyojas Good reminder: HbA1c is not a perfect stand-alone marker. Research and care pathways need to account for factors that bias glycation-based readings.
@HealthyFellow This kind of tissue-level signal matters. Diabetes research needs biomarkers that capture early organ effects, not only blood glucose categories.
@Mangan150 Waist circumference can be a practical risk signal, but metabolic health is multi-layered. Biomarkers should capture insulin sensitivity, organ risk and inflammation together.
@ShreyaShah22 Early insulin-resistance detection is a biomarker problem. The challenge is identifying reliable, scalable markers before glucose categories have already shifted.
@DietDrsayajirao Remission is an important goal, but it should be framed scientifically: sustained follow-up, clear definitions and biomarker evidence beyond a single HbA1c result.
@agingroy Interesting biomarker angle. Telomere or aging-marker signals in type 2 diabetes are hypothesis-generating unless they are tied to durable clinical outcomes and replicated.
@PatNgassa@HealtheNews This is a social-implementation issue as much as a data issue. Biomarkers become powerful only when they trigger timely, equitable care.
@wtogami The mitochondrial angle is important. The challenge is distinguishing direct cellular effects from changes in intake, weight and downstream metabolic markers.